Results 101 to 110 of about 51,273 (262)

Risk of cardiac, neuropsychiatric and musculoskeletal adverse events with levothyroxine: Systematic review

open access: yesBritish Journal of Clinical Pharmacology, EarlyView.
Abstract Levothyroxine (LT4) is the standard treatment for hypothyroidism and the most widely prescribed medication worldwide. Although generally safe, regulatory reports list potential cardiac, neuropsychiatric and musculoskeletal adverse events (AEs). Clarifying their clinical relevance is essential.
Bala Swetha Baskaran   +2 more
wiley   +1 more source

Cold atmospheric plasma‐mediated tumor microenvironment remodeling for cancer treatment

open access: yesBMEMat, EarlyView.
Schematic presentation of CAP‐mediated TME remodeling. This review summarizes recent efforts in cold atmospheric plasma (CAP) application in cancer treatment, highlighting the anticancer potential of CAP, molecular mechanisms, and future perspectives for further improvement and clinical translation.
Israr Khan   +8 more
wiley   +1 more source

Clinical Safety of Extended Interval Dosing of Nivolumab in Patients with Melanoma

open access: yesClinical Pharmacology &Therapeutics, EarlyView.
Extended interval dosing regimens of immune checkpoint inhibitors have been implemented widely. However, their approval was mainly based on pharmacokinetic modeling and simulations. Consequently, comparative safety data of extended interval dosing regimens in a real‐world setting are limited.
Ruben Malmberg   +10 more
wiley   +1 more source

Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibition and Cancer Risk: Insights from a Large Propensity‐Matched Cohort Study

open access: yesClinical Pharmacology &Therapeutics, EarlyView.
Proprotein convertase subtilisin/kexin type 9 (PCSK9) monoclonal antibodies (mAbs) lower LDL cholesterol and may influence cancer through immunomodulatory pathways. However, their effect on human cancer incidence remains unknown. We conducted a retrospective, propensity score‐matched study (Clalit Health Services, Israel, 2010–2023) comparing PCSK9 ...
Inbar Nardi Agmon   +10 more
wiley   +1 more source

Pharmacokinetic Drug–Drug Interaction Potential of Oral Anticancer Drugs

open access: yesClinical Pharmacology &Therapeutics, EarlyView.
Drug–drug interaction (DDI) management is critical for safe and effective use of oral anticancer drugs (OADs). Our study objectives were to (i) compile clinically relevant pharmacokinetic (PK) DDI mechanisms for OADs and (ii) assess the prevalence of PK potential DDIs (PDDIs) in patients with advanced solid cancers.
Fatimah Alhurayri   +10 more
wiley   +1 more source

Phagocytic Mesothelial Cells in Pericardial Effusion Following Allogeneic Peripheral Blood Stem Cell Transplantation for Chronic Active Epstein–Barr Virus Infection: A Distinctive Cytomorphological and Immunocytochemical Case Study

open access: yesDiagnostic Cytopathology, EarlyView.
ABSTRACT Phagocytic activity of mesothelial cells is a rare phenomenon requiring careful differentiation from histiocytic hemophagocytosis to ensure appropriate patient management, as these phenomena could exhibit distinct clinical implications. In this study, we report a case of phagocytic mesothelial cells found in pericardial effusion that developed
Hidetoshi Satomi   +5 more
wiley   +1 more source

Multifocal Benign Metastasizing Pleomorphic Adenoma Presenting as a Lymphoma: An Atypical Clinical Picture Demystified by an Unusual PLAG1 Gene Rearrangement Detected on RNA Next Generation Sequencing

open access: yesDiagnostic Cytopathology, EarlyView.
ABSTRACT A 57‐year‐old female presented to urgent care with exertional dyspnea, back pain, and several months of night sweats. Imaging showed an anterior mediastinal mass with concurrent hepatic and vertebral lesions, raising suspicion for a hematolymphoid malignancy.
Poorva Singh   +3 more
wiley   +1 more source

Annual Banned‐Substance Review 18th Edition—Analytical Approaches in Human Sports Drug Testing 2024/2025

open access: yesDrug Testing and Analysis, EarlyView.
New insights into drug metabolism, distribution, elimination, and detection assays for drugs and methods of sports doping published between 2024 and 2025 are critically reviewed and evaluated in context with the Prohibited List 2025 as established by the World Anti‐Doping Agency.
Mario Thevis, Tiia Kuuranne, Hans Geyer
wiley   +1 more source

Inconsistent Transcriptomic Responses to Hexabromocyclododecane in Japanese Quail: A Comparative Analysis of Results From Four Different Study Designs

open access: yesEnvironmental Toxicology and Chemistry, EarlyView.
Abstract Efforts to use transcriptomics for toxicity testing have classically relied on the assumption that chemicals consistently produce characteristic transcriptomic signatures that are reflective of their mechanism of action. However, the degree to which transcriptomic responses are conserved across different test methodologies has seldom been ...
Paul Béziers   +10 more
wiley   +1 more source

Advanced extracellular vesicle immunotherapy

open access: yesFlexMat, EarlyView.
A diagrammatic depiction of the therapeutic applicability of extracellular vesicles (EVs) in immunotherapy. This review explores the dual roles of tumor‐derived and immune cell‐derived EVs in cancer immunotherapy, discusses recent progress in EV engineering that improve their clinical utility, and evaluates their potential to augment existing ...
Jingjing Zhang   +6 more
wiley   +1 more source

Home - About - Disclaimer - Privacy